Next Article in Journal
The Use of Prophylactic Anticonvulsants in Patients with Brain Tumours—A Systematic Review
Previous Article in Journal
Retinoids, Vitamin D, Invasion, and Metastasis
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 13
Issue 6
10.3747/co.v13i6.124
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia

by
P. Laneuville
1,*,
M.J. Barnett
2,
R. Bélanger
3,
S. Couban
4,
D.L. Forrest
5,
D.C. Roy
6 and
J.H. Lipton
7
1
Division of Hematology, McGill University Health Centre–Royal Victoria Hospital and McGill University, Montreal, QC, Canada
2
Vancouver General Hospital, and British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
3
Department of Hematology, Hôpital Maisonneuve–Rosemont and Université de Montréal, Montreal, QC, Canada
4
Blood and Marrow Transplant Program, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS, Canada
5
Leukemia/BMT Program of BC, British Columbia Cancer Research Centre, and Vancouver Hospital and Health Sciences Centre, Vancouver, BC, Canada
6
Cellular Therapy Laboratory and Program, Hôpital Maisonneuve–Rosemont and Université de Montréal, Montreal, QC, Canada
7
Chronic Myelogenous Leukemia Group, Allogeneic Blood and Marrow Transplant Unit, University Health Network–Princess Margaret Hospital, and University of Toronto, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2006, 13(6), 201-221; https://doi.org/10.3747/co.v13i6.124
Submission received: 1 September 2006 / Revised: 6 October 2006 / Accepted: 3 November 2006 / Published: 1 December 2006

Abstract

Chronic myelogenous leukemia (CML) is a disease characterized by the expression of Bcr/Abl, an oncogenic protein tyrosine kinase, and by evolution over time from a relatively benign chronic phase to a rapidly fatal CML blast crisis. Until recently, the standard of care included potentially curative therapy with allogeneic stem cell transplantation, available only to a minority (about 10%) of patients, or medical therapy with interferon-α with or without cytarabine, which helped to prolong the chronic phase of the disease in a minority of patients. The availability of imatinib mesylate, a selective inhibitor of Bcr/Abl approved by Health Canada in 2001, has profoundly altered the clinical and laboratory management of CML. This change in practice has been reviewed by the Canadian Consensus Group on the Management of Chronic Myelogenous Leukemia and has resulted in a new set of recommendations for the optimal care of CML patients.
Keywords: chronic myeloid leukemia; clinical practice guideline; imatinib chronic myeloid leukemia; clinical practice guideline; imatinib

Share and Cite

MDPI and ACS Style

Laneuville, P.; Barnett, M.J.; Bélanger, R.; Couban, S.; Forrest, D.L., 5; Roy, D.C.; Lipton, J.H. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia. Curr. Oncol. 2006, 13, 201-221. https://doi.org/10.3747/co.v13i6.124

AMA Style

Laneuville P, Barnett MJ, Bélanger R, Couban S, Forrest DL 5, Roy DC, Lipton JH. Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia. Current Oncology. 2006; 13(6):201-221. https://doi.org/10.3747/co.v13i6.124

Chicago/Turabian Style

Laneuville, P., M.J. Barnett, R. Bélanger, S. Couban, D.L. Forrest 5, D.C. Roy, and J.H. Lipton. 2006. "Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia" Current Oncology 13, no. 6: 201-221. https://doi.org/10.3747/co.v13i6.124

APA Style

Laneuville, P., Barnett, M. J., Bélanger, R., Couban, S., Forrest, D. L., 5, Roy, D. C., & Lipton, J. H. (2006). Recommendations of the Canadian Consensus Group on the Management of Chronic Myeloid Leukemia. Current Oncology, 13(6), 201-221. https://doi.org/10.3747/co.v13i6.124

Article Metrics

Back to TopTop